



siRNAgen Therapeutics Begins Phase 1b Trial for SRN-001

- **Protocol Amendment Complete, Phase 1b Accelerates**
- **Strategic Partnering with Global Pharma at BIO USA 2026**

siRNAgen Therapeutics (siRNAgen) has completed the application and approval process for a protocol amendment to its Phase 1b trial of SRN-001 (SAMiRNA-AREG, telfirosiran), a drug candidate for idiopathic pulmonary fibrosis (IPF), chronic kidney disease (CKD), and end-stage renal disease (ESRD). Starting in July, the company plans to begin recruiting and screening healthy adult subjects in earnest.

siRNAgen plans to complete the Phase 1b multiple ascending dose (MAD) study as scheduled in the second half of this year, securing safety, pharmacokinetic (PK), target engagement, and pharmacodynamic (PD) data.

The company will treat this as a milestone that raises its corporate value and move forward with discussions on co-development, strategic partnerships, and licensing-out with global pharmaceutical companies.

siRNAgen has also set up a proactive manufacturing strategy to enable rapid initiation of follow-on trials. It has signed an additional contract with the CMO that produced drug supply for the Phase 1b trial, and plans to complete production of about 20,000 doses of investigational drug for follow-on trials by the end of this year.

Bioneer and siRNAgen presented SRN-001's clinical development status and preclinical research results across multiple indications to global pharmaceutical and biotech companies at BIO USA, held June 22–25 in San Diego, and held in-depth discussions on potential co-development, clinical collaboration, and licensing-out.

The multi-indication strategy — expanding a single platform across multiple indications — drew particular interest from global pharma companies. SRN-001 is viewed as a platform asset that can be developed against a single target, amphiregulin, for uses spanning pulmonary fibrosis, renal fibrosis, radiation-induced fibrosis, and combination cancer therapy.

The technical differentiation of the SAMiRNA® platform also drew strong interest. SAMiRNA® is a supramolecular siRNA drug delivery platform that enables in vivo delivery without a separate carrier, addressing the delivery efficiency and safety issues of conventional siRNA therapeutics. Global pharma companies showed keen interest in the platform's scalability and applicability across a range of diseases.

Amphiregulin (AREG) has drawn attention as a key factor overexpressed in various solid tumors, modulating the tumor microenvironment (TME) and driving tumor fibrosis in ways that impair response to chemotherapy and immunotherapy. SRN-001 is generating interest as a new combination therapy strategy that could simultaneously address tumor fibrosis and the immunosuppressive microenvironment.

Research published in the journal Nature showing that increased amphiregulin expression after radiation therapy can promote cancer progression and metastasis has also drawn attention to amphiregulin-targeted therapy as a potential companion therapy — enhancing radiation efficacy while suppressing recurrence and metastasis.

SRN-001 is a drug candidate that targets two growth areas where global pharmaceutical companies are actively investing: fibrosis and tumor microenvironment modulation.

The company will continue conducting preclinical efficacy studies to explore expansion into a range of diseases, including cancer.





A “Disruption-to-Analysis” Full-Workflow Solution A First Step Into the Green Bio Market

ExiBeater™ Draws Attention at KSABC Symposium

Bioneer is moving beyond medical molecular diagnostics to target the high-growth green bio (agriculture, food, and natural products) genomic analysis market.

Bioneer took part in the Korean Society for Applied Biological Chemistry (KSABC) International Symposium, held June 21–24 at the Jeju ICC. There, the company showcased a “full-workflow” solution covering everything from sample disruption to nucleic acid extraction and real-time PCR analysis, drawing attention from researchers in Korea and abroad.



The green bio industry has recently seen a surge in molecular-level, high-throughput screening research — from developing new crop varieties for climate resilience to microbiome-based functional food research and the adoption of CRISPR gene-editing technology. However, samples such as plant tissue, soil, and fermented foods have tougher structures than medical samples like blood, and contain more PCR inhibitors such as polysaccharides and polyphenols, creating a persistent challenge in achieving reproducible results.



Bioneer has introduced an automated lineup to solve these pain points. In the sample pretreatment stage, the powerful disruption instrument ExiBeater™ uniformly breaks down hard seeds, tough plant leaves, and thick-walled microbial samples in just seconds, reducing experimental variability.

Next, the nucleic acid extraction instrument ExiPrep™ 96 Lite, paired with the EcoQprep™ Plant Genomic DNA & Universal RNA Extraction Kit — built on Bioneer's proprietary magnetic nanoparticle technology — simultaneously extracts high-purity nucleic acid from 96 samples with no human error.

In the final analysis stage, the lyophilized premix reagent AccuPower® GreenStar™ qPCR PreMix combines with the real-time PCR instrument ExiCycler™ V5 to guarantee consistent, precise gene expression results regardless of the researcher's skill level.




At the symposium, Bioneer held in-depth discussions with researchers in future foods and health functional foods — a blue-ocean segment of the green bio market.


To gain approval for a functional health food ingredient from Korea's Ministry of Food and Drug Safety (MFDS), objective efficacy data — such as biomarkers — are required. Bioneer presented efficient verification strategies to researchers developing ingredients for special-purpose foods, such as edible insects, medical foods, and foods for the elderly.

Bioneer showcased its Health Functional Food Biomarker Panel Kit, which packages the gene reagents needed for such testing, and also proposed a qPCR array testing service that runs large-scale real-time PCR analysis on behalf of companies that lack in-house testing capacity.

Bioneer also gathered practical feedback from researchers for future product improvements. Specific requests included a customizable protocol feature to accommodate varied green bio sample conditions and a cooling function to improve final yield and purity during nucleic acid extraction. Bioneer plans to actively incorporate this feedback into future equipment and reagent development guidelines.



▲ Bioneer Health Functional Food Biomarker Panel Kit



Multiplex Testing Is Now Essential Spotlight on IRON-qPCR™

Bioneer exhibited at the 2026 Korean Society of Clinical Microbiology (KSCM) conference, held June 18–19, introducing its core molecular diagnostic system IRON-qPCR™, designed to address diagnostic trends shifting in response to the spread of antibiotic resistance.

The infectious disease field is rapidly shifting toward complex, multiplex testing needs — including carbapenem-resistant Enterobacteriaceae (CRE), multidrug-resistant and pre-extensively drug-resistant tuberculosis (TB, MDR-TB, Pre-XDR-TB), and sexually transmitted infections (STIs). As a result, hospitals increasingly need molecular diagnostic platforms that can analyze multiple pathogens faster and more accurately at once.

IRON-qPCR™ is a core platform designed to meet this clinical demand, with the strength of broad scalability for diagnosing antibiotic-

resistant pathogens and major infectious diseases.

Bioneer highlighted IRON-qPCR™'s capability as a multiplex point-of-care platform that can detect CRE genes as well as TB and its drug-resistance subtypes — MDR-TB and Pre-XDR-TB — in a single test, presenting a practical vision for clinical solutions in hospital infection and disease control.

The system also drew strong visitor interest for its space-efficient design, which minimizes lab installation constraints, and its fully automated 40-minute turnaround for rapid testing.

The combination of clinical usefulness and operational convenience makes IRON-qPCR™ easy to adopt not only at large tertiary hospitals but also at smaller secondary hospitals, earning positive feedback from laboratory medicine specialists and other professionals who visited the booth.

The conference also drew a number of key clinicians and opinion leaders from the Japanese Society for Clinical Microbiology (JSCM), which maintains close academic ties with KSCM. Japanese medical professionals who visited Bioneer's booth expressed strong interest in the company's diagnostic solution for scrub typhus, a major endemic disease common to both Korea and Japan — a meaningful sign of future demand and market expansion potential for Bioneer's diagnostic kits across the APAC region.

Through its booth at the conference, the

company actively promoted its technology and applicability to clinical experts at home and abroad, and plans to expand collaboration with hospitals and research institutions going forward. This underscores how closely Bioneer's infectious disease molecular diagnostics portfolio is aligned with the needs of today's clinical customers.

A Bioneer official said, "Antibiotic resistance will be a central topic in the infectious disease diagnostics market going forward," adding, "We will build market trust and accelerate business growth by providing diagnostic solutions optimized for the evolving clinical landscape, centered on IRON-qPCR™."



▲ Bioneer IRON-qPCR™



▲ Bioneer's booth at the KSCM conference



CosmeRNA at The Aesthetic Show Las Vegas 2026

Pushing Into the World's Largest Hair Care Market

▲ CosmeRNA's booth at The Aesthetic Show Las Vegas

- Local Distributor & KOL Networks
- Diversifying Sales via US, Amazon, Direct Sales

Bioneer exhibited at The Aesthetic Show Las Vegas 2026, held June 25–28 in Las Vegas, promoting its premium RNA-technology-based scalp care brand CosmeRNA and carrying out global marketing and sales activities to enter the U.S. scalp care market.

At the event, Bioneer held one-on-one consultations with key local buyers, distributors, and clinic and aesthetics professionals, and discussed business collaboration with prospective new distributors.

Specifically, Bioneer engaged professionals across categories such as key opinion leaders, MedSpas, spas, salons, scalp care specialists, and sports wellness experts, encouraging product trial and conducting business discussions. Local response to CosmeRNA was positive, and the company confirmed potential for sales growth through professional recommendations and conversion to online purchases. This secured potential distribution channels, including distributors, and laid the groundwork for boosting direct-to-consumer sales.



Bioneer strengthened CosmeRNA's positioning as a "premium RNA-technology-based scalp home care routine brand," emphasizing its accessibility as a home care product for everyday consumers while discussing with key opinion leaders how to recommend the product to customers and apply it within home care routines. The company also proposed potential collaborations such as clinical case studies and joint content creation.

Bioneer plans to operate a CosmeRNA KOL Group made up of key experts met at the event to strengthen global promotion and boost product credibility, and will further extend this into activities such as producing academic content and entering industry awards.

Bioneer has completed CosmeRNA's MOCRA registration (facility registration and product listing), meeting the regulatory requirements needed for distribution in the U.S. market. CosmeRNA has also built global product competitiveness and scientific credibility by winning first place in the hair care category at Cosmoprof Bologna 2024 and being published in Scientific Reports.

Building on this event, Bioneer plans to pursue U.S. distributor agreements leading to initial orders, while also expanding online channels such as Amazon US and its own online store. This will diversify the company's global sales structure and strengthen CosmeRNA's brand position in the U.S. market.



CosmeRNA Hosts a Seminar at ACAIC 2026

Expanding Ties With Global Dermatologists



▲ Dr. Mukta Sachdev presenting at CosmeRNA's dedicated seminar at ACAIC 2026

Bioneer took part in ACAIC 2026 (Asian Clinical Aesthetic Innovations Conference), held June 27 at the Harvard Club of New York City, and hosted a dedicated seminar for physicians and researchers. ACAIC is a specialized academic event drawing more than 200 global dermatologists, including researchers and industry professionals based in the U.S.

The seminar, hosted by Bioneer, was titled "CosmeRNA in Hair Restoration: In-Clinic

Experience, Clinical Insights and Emerging Practice Opportunities." Dr. Mukta Sachdev (India) and Dr. Hee Jin Kim (U.S.) spoke as presenters, sharing their in-clinic experience and observations using CosmeRNA and engaging in an active discussion on its potential applications in hair restoration.

CosmeRNA
SCALP REVITALIZING SERUM
피부스킨케어 에이징라이프 스킨케어

The seminar focused on CosmeRNA's three main use cases — post-transplant maintenance, long-term hair care, and hair wellness — sharing real-world usage experience and future potential. Attending clinicians exchanged views on practical applications such as combining CosmeRNA with existing hair care programs, integrating it into professional programs, and long-term management strategies, showing strong interest in this RNA-technology-based cosmetic.

Notably, Dr. Daniel M. Siegel — a past president and honorary member of the American Academy of Dermatology (AAD) and clinical professor of dermatology at SUNY Downstate Health Sciences University — attended CosmeRNA's seminar. He added academic depth to the session with in-depth questions on clinical applications and future directions in hair restoration.

Through its participation in ACAIC 2026, Bioneer plans to continue expanding its network with global dermatologists and strengthening the

foundation for KOL collaboration and overseas market expansion.



▲ CosmeRNA team member at the conference



▲ ACAIC 2026 CosmeRNA promotional banner





AceBiome's BNRThin (4 Products) Enters Olive Young USA Retail

AceBiome has launched four products from its flagship body-fat-reduction probiotic brand BNRThin simultaneously across Olive Young USA's online and offline channels, expanding its reach with U.S. consumers. The four products introduced to the U.S. market are BNRThin S30, BNRThin R, BNRThin Slim+, and BNRThin Protein.

AceBiome was one of the launch brands at Olive Young USA's first store, which opened in Pasadena, California in May, laying the groundwork for entering North America's offline retail market. This marks a meaningful milestone as a microbiome-based health functional food brand grown in Korea entering the U.S. offline retail market.

BNRThin S30, built around AceBiome's patented *Lactobacillus gasseri* BNR17 strain, is a U.S.-tailored product formulated to support both body fat and gut health with one capsule a day. BNRThin R adds a prebiotic ingredient; BNRThin Slim+ is a convenient stick-pack format; and BNRThin Protein is a powder that combines BNR17 probiotics with a high protein content,

addressing muscle and bone health alongside body fat and gut health.

By launching four flagship products at once at Olive Young USA, the company has expanded the options available to North American consumers under the BNRThin brand, introducing them to the differentiated concept of a body-fat-reduction probiotic as a K-health and inner-beauty brand. AceBiome plans to build brand awareness and expand its consumer touchpoints through Olive Young's offline stores and its dedicated U.S. online store.

AceBiome plans to strengthen its brand positioning around sustainable weight management and gut health across Olive Young USA's online and offline stores. This launch is expected to further solidify BNRThin's standing as a body-fat-management probiotic brand in the global K-health and inner-beauty market.

AceBiome Launches BNRTThin S30 on U.S. Home Shopping



1등 다이어트 유산균*

BNRThin S30

누적판매 1조 돌파**

- ✓ 2중 기능성 - 체지방 감소 & 장 건강
- ✓ *L. gasseri* BNR17® 100억 마리 보장
- ✓ 해외 건강기능 원료 대회 2관왕 석권

*국내 가우 네 다이어트 유산균 내 구획에 시장점유율 3년 연속 1위 (Worldpanel by Numerator, 2023.01.02~2025.12.28)
**세계남반 보편적 매출액 기준(2018.11~2025.09)



TV · 온라인 동시 방송 6월 18일 Shop LC LIVE에서 만나보세요!



AceBiome introduced BNRTThin S30 on the U.S. home shopping channel Shop LC, expanding its distribution reach in the North American market. The broadcast aired at 4 p.m. Central Time, allowing U.S. consumers to watch and purchase the product not only on local TV but also via Shop LC LIVE's website stream and mobile app.

BNRTThin S30 is a U.S.-tailored version of AceBiome's body-fat-management probiotic brand BNRTThin, designed for simple once-daily intake. Its core ingredient, *Lactobacillus gasseri* BNR17, is a patented probiotic strain isolated from Korean breast milk and the first individually approved ingredient in Korea recognized for body-fat-reduction functionality. This home shopping launch is meaningful as a case of introducing BNR17-based body fat and gut health benefits directly to U.S. consumers, conveying the product's scientific backing and ease of use to the local market.

This launch, following the recent placement of four BNRTThin products at Olive Young USA's first store, extends AceBiome's reach into home shopping and online live commerce — a further step in diversifying its U.S. distribution.

Notably, BNRTThin S30 exceeded its target sales during the launch broadcast, confirming both sales potential on U.S. home shopping channels and local consumer demand. Combining TV broadcast, website live streaming, and a mobile app improved accessibility for U.S. consumers and provided an early read on market response in North America.

Building on the success of the Shop LC launch, AceBiome plans to expand its home shopping and online sales channels in the U.S. The company will also strengthen the differentiated functionality and brand credibility of its BNR17-based diet probiotics, linking home shopping with online and offline channels in the U.S. to accelerate brand awareness and sales growth in North America.